KR102752108B1 - 단일 면역글로불린 인터류킨-1 수용체 관련(sigirr) 변이체 및 이의 용도 - Google Patents

단일 면역글로불린 인터류킨-1 수용체 관련(sigirr) 변이체 및 이의 용도 Download PDF

Info

Publication number
KR102752108B1
KR102752108B1 KR1020207009809A KR20207009809A KR102752108B1 KR 102752108 B1 KR102752108 B1 KR 102752108B1 KR 1020207009809 A KR1020207009809 A KR 1020207009809A KR 20207009809 A KR20207009809 A KR 20207009809A KR 102752108 B1 KR102752108 B1 KR 102752108B1
Authority
KR
South Korea
Prior art keywords
nucleic acid
seq
sigirr
acid molecule
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207009809A
Other languages
English (en)
Korean (ko)
Other versions
KR20200058435A (ko
Inventor
클라우디아 지. 곤자가-자우리구이
줄리에 호로윗즈
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Publication of KR20200058435A publication Critical patent/KR20200058435A/ko
Application granted granted Critical
Publication of KR102752108B1 publication Critical patent/KR102752108B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020207009809A 2017-09-06 2018-09-05 단일 면역글로불린 인터류킨-1 수용체 관련(sigirr) 변이체 및 이의 용도 Active KR102752108B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762554857P 2017-09-06 2017-09-06
US62/554,857 2017-09-06
PCT/US2018/049478 WO2019050899A1 (en) 2017-09-06 2018-09-05 SINGLE IMMUNOGLOBULIN INTERLEUKIN 1 (SIGIRR) RELATED INTERCEPTOR-RELATED VARIANTS AND USES THEREOF

Publications (2)

Publication Number Publication Date
KR20200058435A KR20200058435A (ko) 2020-05-27
KR102752108B1 true KR102752108B1 (ko) 2025-01-10

Family

ID=63708447

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207009809A Active KR102752108B1 (ko) 2017-09-06 2018-09-05 단일 면역글로불린 인터류킨-1 수용체 관련(sigirr) 변이체 및 이의 용도

Country Status (15)

Country Link
US (1) US20210071251A1 (cg-RX-API-DMAC7.html)
EP (1) EP3679158B1 (cg-RX-API-DMAC7.html)
JP (1) JP7237064B2 (cg-RX-API-DMAC7.html)
KR (1) KR102752108B1 (cg-RX-API-DMAC7.html)
CN (1) CN111373053B (cg-RX-API-DMAC7.html)
AU (1) AU2018328120B2 (cg-RX-API-DMAC7.html)
CA (1) CA3074652A1 (cg-RX-API-DMAC7.html)
DK (1) DK3679158T3 (cg-RX-API-DMAC7.html)
ES (1) ES3034207T3 (cg-RX-API-DMAC7.html)
FI (1) FI3679158T3 (cg-RX-API-DMAC7.html)
IL (1) IL272940B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020002643A (cg-RX-API-DMAC7.html)
NZ (1) NZ762152A (cg-RX-API-DMAC7.html)
SG (1) SG11202001754RA (cg-RX-API-DMAC7.html)
WO (1) WO2019050899A1 (cg-RX-API-DMAC7.html)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
AU693097B2 (en) 1993-06-04 1998-06-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for treating kaposi's sarcoma with antisense oligonucleotides
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
EP0775204A1 (en) 1994-08-09 1997-05-28 Novartis AG Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
WO1997014709A1 (en) 1995-10-13 1997-04-24 F. Hoffmann-La Roche Ag Antisense oligomers
JPH11507245A (ja) 1995-11-21 1999-06-29 アイシーエヌ・ファーマシューティカルズ・インコーポレイテッド Il―8およびil―8受容体に対するアンチセンスオリゴヌクレオチドによる睡瘍増殖の阻害
AU708535B2 (en) 1996-02-15 1999-08-05 Cleveland Clinic Foundation, The RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
IL136696A0 (en) * 1997-12-23 2001-06-14 Immunex Corp Sigirr dna and polypeptides
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
WO2013176772A1 (en) 2012-05-25 2013-11-28 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
LT3138910T (lt) 2012-12-06 2017-11-10 Sigma-Aldrich Co. Llc Crispr pagrįstas genomo modifikavimas ir reguliavimas
EP4230648A3 (en) 2016-07-28 2023-10-18 Regeneron Pharmaceuticals, Inc. Gpr156 variants and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Drug Discov Today Dis Mech. 2011 Winter; 8(3-4): e63-e69.
Front Immunol. 2012; 3: 322.
World J Gastroenterol. Jan 21, 2008; 14(3): 390-400

Also Published As

Publication number Publication date
IL272940B1 (en) 2024-02-01
SG11202001754RA (en) 2020-03-30
DK3679158T3 (da) 2025-06-23
CN111373053B (zh) 2024-07-30
JP2020537495A (ja) 2020-12-24
EP3679158B1 (en) 2025-04-30
FI3679158T3 (fi) 2025-06-18
RU2020112474A (ru) 2021-10-06
JP7237064B2 (ja) 2023-03-10
CN111373053A (zh) 2020-07-03
MX2020002643A (es) 2020-09-25
AU2018328120B2 (en) 2024-11-14
KR20200058435A (ko) 2020-05-27
NZ762152A (en) 2025-11-28
ES3034207T3 (en) 2025-08-13
CA3074652A1 (en) 2019-03-14
AU2018328120A1 (en) 2020-03-19
US20210071251A1 (en) 2021-03-11
WO2019050899A1 (en) 2019-03-14
EP3679158A1 (en) 2020-07-15
RU2020112474A3 (cg-RX-API-DMAC7.html) 2021-12-29
IL272940B2 (en) 2024-06-01
IL272940A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
US11155598B2 (en) GPR156 variants and uses thereof
US20220017964A1 (en) Cornulin (CRNN) Variants And Uses Thereof
KR102752108B1 (ko) 단일 면역글로불린 인터류킨-1 수용체 관련(sigirr) 변이체 및 이의 용도
RU2815068C2 (ru) Варианты белка, родственного рецептору интерлейкина-1 и содержащего одиночный домен иммуноглобулина (sigirr), и их применение
US20210230609A1 (en) Solute Carrier Family 14 Member 1 (SLC14A1) Variants And Uses Thereof
HK40033837A (en) Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
HK40033837B (en) Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
HK40098517A (en) Gpr156 variants and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200403

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210901

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240207

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241126

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250106

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250107

End annual number: 3

Start annual number: 1

PG1601 Publication of registration